Kincell Bio Strengthens Leadership With The Appointment Of Stewart McNaull As The New Chief Commercial Officer

Kincell Bio, a prominent cell therapy development and manufacturing company, has appointed Dr. Stewart McNaull as its new Chief Commercial Officer (CCO). Dr. McNaull brings over 25 years of experience in the biopharmaceutical industry, with a strong background in advanced therapy  Contract Development and Manufacturing Organization (CDMO). Known for his technical expertise and strategic approach, Stewart will be significant in driving Kincell’s growth and reinforcing its dedication to supporting cell therapy innovators and the patients they serve.

Stewart McNaull, expressed his excitement about his new role by saying, “I am thrilled to join the highly talented team to advance Kincell’s cell therapy service offerings. It is refreshing to return to the cell therapy space where my knowledge of CMC development can help design technical and business solutions that uniquely advance our clients’ products to the clinic.”

Before joining Kincell Bio, Dr McNaull led key roles at Wheeler Bio, Resilience, KBI, Fujifilm, and Bayer. His in-depth knowledge of the CDMO sector and ability to tailor business and technical solutions to client needs make him exceptionally suited to delivering impactful, high-quality services.

Bruce Thompson, PhD, CEO of Kincell Bio, also commented, “Stewart’s extensive commercial leadership and technical operations background makes him an invaluable addition to our team. As we expand our capabilities and enhance our service offerings, Stewart’s insights and industry relationships will be instrumental in fostering partnerships that drive our clients' success and improve patient outcomes.”

Kincell Bio has focused on cell therapy with customized solutions to place these therapies into more commercial and faster-to-market realities. The appointment of Stewart as the new CCO speaks to the most important step taken by Kincell Bio in supporting and expanding its services to meet changing client demands.